drugset / Trial / NCT00205764

Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy

NCT00205764

Phase 3 Completed 212 enrolled Austrian Forum Against Cancer
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an international,multicenter, prospective, open, double randomised and controlled phase III study to compare the therapeutic efficacy of tandem high dose Melphalan versus triple intermediate dose Melpahaln in newly-diagnosed myeloma patients

Timeline

Start
1999-03
Primary completion
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan Small molecule 100 mg/m2
Subject Melphalan Small molecule 200 mg/m2

Indications